# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN
- Date: 2026-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week check after adding chlorthalidone. **S**

## History of present illness

Mr. Washington returns four weeks after chlorthalidone was added. His home readings run in the 120s and low 130s over 70s and 80s. He has had no headaches for six weeks, and his concentration is a little better. He has had no lightheadedness on standing, muscle cramps, or joint pain, and he takes all five medicines every morning from a weekly organizer. He still gets up once or twice a night to urinate. **S**

| Element | Detail |
|---|---|
| Home blood pressure | 120s to low 130s over 70s to 80s |
| Symptoms | No headaches for six weeks; concentration a little better |
| Medication tolerance | No lightheadedness, cramps, or joint pain on chlorthalidone |
| Adherence | Weekly organizer; every dose taken |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight stable |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No cramps or joint pain |
| Genitourinary | Positive | Up once or twice a night to urinate; no dysuria |
| Neurological | Negative | No headache or lightheadedness on standing |

5 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/80 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 70 kg; BMI 24.2 kg/m². All vital signs are synthetic.

Sodium: 135 mmol/L; Potassium: 4.3 mmol/L; Bicarbonate (total CO2): 23 mmol/L; BUN: 36 mg/dL (high); Creatinine: 2.4 mg/dL (high); eGFR: 30 mL/min/1.73 m² (low); Glucose: 96 mg/dL; Urine albumin-creatinine ratio: 360 mg/g (high). All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 135 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Bicarbonate (total CO2): 21 mmol/L (low) at baseline, 23 mmol/L at this visit **S**
- BUN: 34 mg/dL (high) at baseline, 36 mg/dL (high) at this visit **S**
- Creatinine: 2.1 mg/dL (high) at baseline, 2.4 mg/dL (high) at this visit **S**
- eGFR: 36 mL/min/1.73 m² (low) at baseline, 30 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 96 mg/dL at this visit **S**
- Urine albumin-creatinine ratio: 820 mg/g (high) at baseline, 360 mg/g (high) at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 128/80 mmHg, the average of two seated readings after five minutes' rest; no fall on standing |
| Heart | Regular rhythm, rate 74; soft S4 |
| Lungs | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe hypertension with hypertensive kidney disease, controlled below 130/80** (I12.9). Blood pressure 128/80 mmHg on four medicines, meeting the goal of below 130/80 within two months. The KDIGO systolic target below 120 is not yet reached, but home readings are still falling. **S**
   - No change today; the full effect of chlorthalidone and the lower-sodium diet can take several more weeks.
   - Recheck at the preventive visit and the six-month review.
2. **Chronic kidney disease stage G3b A3** (N18.32). Creatinine 2.4 mg/dL and eGFR 30, unchanged since the last check; potassium 4.3 and sodium 135 mmol/L on chlorthalidone. Urine albumin-creatinine ratio 360 mg/g, down 56 percent from 820, already beyond the 30 percent goal though still severely increased. **S**
   - Continue the current regimen.
   - Hepatitis B vaccine dose 2 today, completing the series.
   - eGFR, urine albumin, hemoglobin, calcium, phosphate, PTH, vitamin D, and the kidney failure risk at the six-month review.
3. **Hyperlipidemia** (E78.5). Taking atorvastatin 20 mg daily without muscle symptoms. **S**
   - No repeat LDL, per KDIGO.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | Four weeks after starting chlorthalidone. Potassium 4.3, sodium 135 (low-normal), creatinine 2.4 mg/dL, eGFR 30: stable |
| Laboratory | Urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Completed today | 360 mg/g, down 56 percent from 820; still A3 |
| Laboratory | eGFR and urine albumin, next pair | About 3 times a year for G3b A3 | Due | Next at the six-month review, in about four months |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Due | At the six-month review |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Due | Planned with the six-month calcium, phosphate, and PTH |
| Laboratory | Hemoglobin | At least yearly in G3 | Due | At the six-month review |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Due | At the six-month review |
| Laboratory | Lipid panel | Once at diagnosis in chronic kidney disease; 4 to 12 weeks after a statin start in the lipid monograph | Not indicated | LDL 138 mg/dL at diagnosis. The CKD monograph and KDIGO advise against routine follow-up LDL testing once a statin is started, and the care plan follows them; this departs by choice from the lipid monograph's 4 to 12 week panel, whose window is now open |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 128/80 mmHg; below 130/80 but above the systolic target of 120 |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70 kg; soft S4 |
| Medication safety | Chlorthalidone safety | Each visit while starting | Completed today | Sodium 135 and potassium 4.3; no orthostatic fall, cramps, or gout |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs; doses checked for eGFR 30 |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | Hepatitis B vaccine dose 2 today; influenza vaccine due in the fall |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; walking most days |

## Goal progress

- Lower blood pressure below 130/80 within two months. Outcome by 2026-06-29: Blood pressure 128/80 on four medicines. **S**
- Reach a standardized office systolic pressure below 120 when tolerated by the six-month review. In progress; target 2026-10-26. **S**
- Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review. In progress; target 2026-10-26. **S**
- Keep eGFR decline after starting therapy within 30 percent and stable thereafter. In progress; target 2026-10-26. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge

## Follow-up

- Preventive visit in September. Six-month blood pressure and kidney review with eGFR, urine albumin, hemoglobin, calcium, phosphate, PTH, vitamin D, and the kidney failure risk. **S**
- Next scheduled visit 2026-09-21: periodic adult preventive visit. **S**
